JavaScript is disabled in your browser. Please enable JavaScript to view this website.

TNFRSF11B

GeneName

TNFRSF11B

Summary

TNFRSF11B, also known as OPG or osteoprotegerin, is a 46 kDa secreted glycoprotein that plays a vital role in bone metabolism and immune regulation. It is primarily expressed in the extracellular matrix and extracellular space, as well as at the plasma membrane of various cell types. OPG functions as a decoy receptor for RANKL (receptor activator of nuclear factor kappa-B ligand), inhibiting osteoclast differentiation and activity, thereby preventing bone resorption. Additionally, it is involved in regulating apoptotic processes and has a role in the organisation of the extracellular matrix. Its interactions include heparan sulfate binding and signalling receptor activity, contributing to various signalling pathways within the skeletal system.

Importance

TNFRSF11B is relevant to: - Bone health and osteoporosis through its regulation of osteoclast differentiation and activity - Cancer biology, as it modulates the tumour necrosis factor-mediated signalling pathway, impacting tumour progression and metastasis - Cardiovascular diseases, given its role in vascular remodelling and inflammation - Dental health, due to its involvement in odontogenesis and the development of dentin-containing teeth

Top Products

For researchers investigating TNFRSF11B, we recommend two excellent primary antibodies. The first is the well-cited polyclonal antibody, Anti-Osteoprotegerin antibody (ab73400), which has garnered 107 citations, highlighting its reliability in the field. This antibody is particularly effective for Western blotting (WB), immunohistochemistry (IHC), and immunocytochemistry (ICC). In addition, we offer the recombinant antibody, Anti-Osteoprotegerin antibody [EPR3592] (ab124820). This monoclonal antibody is validated for use in IHC and ICC, providing researchers with the consistency and performance that recombinant antibodies are known for. Together, these products offer a robust toolkit for studying TNFRSF11B. The Recombinant Human TR11B Protein (Active) ELISA Kit (ab287918) is an excellent option for researchers looking to measure TNFRSF11B in their experiments.

Abcam Product Citation Summary

The data indicates that TNFRSF11B is being studied in various contexts, particularly in relation to osteoclast formation, inflammatory cytokines, and cellular responses under hypoxic conditions. The use of multiple antibodies across different species, including human and rat, highlights the relevance of TNFRSF11B in both basic and applied research settings.

Abcam Product Citation Table

Product Code
Species
Application
Study Context
PMID
ab100617
Human
Cell culture supernatant of LDSCs and ADSCs
30544806
ab183910
Mouse
WB
Osteoclast formation
31088250
ab73400
Rat
ICC/IHC
Inflammatory cytokines
26270535
ab73400
Human
WB
32027437
ab73400
Rat
WB
BMSC dysfunction under hyperglycemic conditions
31929852
ab73400
Human
WB
Hypoxia
32027437
ab73400
Human
WB
Regulation of A20
32027437
ab73400
Human
WB
Autophagy under hypoxia
32027437

Function

Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

Involvement in disease

Paget disease of bone 5, juvenile-onset

PDB5

An autosomal recessive, juvenile-onset form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone. PDB5 clinical manifestations include short stature, progressive long bone deformities, fractures, vertebral collapse, skull enlargement, and hyperostosis with progressive deafness.

None

The disease is caused by variants affecting the gene represented in this entry.

Post-translational modifications

N-glycosylated. Contains sialic acid residues.

The N-terminus is blocked.

Tissue Specificity

Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.

Cellular localization

Alternative names

OCIF, OPG, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin

swissprot:O00300 omim:602643 entrezGene:4982

Other research areas